Sodium-glucose cotransporter 2 inhibitor

DRUG4 trials

Sponsors

Fondazione Schena, Mayo Clinic, Assiut University, Queen's University, Belfast

Conditions

Cardiac DiseaseChronic Heart DiseaseGlomerulonephritisHeart FailureImmunoglobulin A NephropathySGLT2 Inhibitiors Remodeling EffectType 2 Diabetes

Phase 4

Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

RecruitingNCT04662723

Fondazione SchenaGlomerulonephritis, Immunoglobulin A Nephropathy

Start: 2023-05-01End: 2028-12-31Target: 878Updated: 2025-04-02

Unknown Phase

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

CompletedNCT05214573

Mayo ClinicCardiac Disease, Type 2 Diabetes

Start: 2021-12-01End: 2025-07-22Updated: 2025-10-10

Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure

Queen's University, BelfastHeart Failure

Start: 2023-08-21End: 2025-05-01Target: 68Updated: 2023-11-18

Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure

Assiut UniversityChronic Heart Disease, SGLT2 Inhibitiors Remodeling Effect

Start: 2023-12-01End: 2024-12-31Target: 98Updated: 2023-11-18

Related Papers

Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk

Clinical Journal of the American Society of Nephrology2024-10-084 citations

Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk.

2024-04-0310 citations